Special Issue

Biologics for Bone and Soft Tissue Regeneration: What Is New, What Is True—Second Edition

Message from the Guest Editors

The increasing applications of biologic therapies in regenerative medicine have led to considerable marketing efforts, patient demand, and clinical use. This collection highlights the current status of these biologic therapies and challenges and emerging trends in their use for regenerating musculoskeletal tissues, including bone and soft tissues. We welcome the submission of original research and review articles covering both fundamental and translational studies on topics including, but not limited to, the following:

- The mechanisms of action of these biologics' therapeutic effects;
- The therapeutics effects of these biologics in regenerating bone and/or soft tissue(s);
- Comparisons of therapies using these biologics to the current standard treatments;
- Identifying research gaps to guide future research and streamline the translation to clinical utilization.

We look forward to receiving your valuable contributions.

Guest Editors

Dr. Ashim Gupta

Future Biologics, Lawrenceville, GA 30043, USA

Prof. Dr. Nicola Maffulli

- 1. Department of Trauma and Orthopaedics, Sapienza University, Roma, Italy
- 2. Barts and The London School of Medicine and Dentistry, Mile End Hospital, Queen Mary University of London, 275 Bancroft Road, London E1 4DG, UK
- 3. School of Pharmacy and Bioengineering, Keele University Faculty of Medicine, Thornburrow Drive, Stoke on Trent ST4 7QB, UK

Dr. Erwin Pavel Lamparelli

Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy

Deadline for manuscript submissions

31 January 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/243877

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).